Vivet Therapeutics is committed to developing an innovative liver-directed gene therapy platform for the treatment of rare and severe inherited metabolic disorders. The company's development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes.
Vivet's focus is on developing innovative gene therapy technologies and treatments for Wilson disease, Progressive Familiar Intrahepatic Cholestasis, Cirtullinemia and other indications. Vivet's platform leverages new AAV-serotypes, advanced GMP manufacturing processes, disease models and innovative technologies to address current challenges in AAV-based gene therapy.
|Size (employees)||17 (est)|
Vivet Therapeutics total Funding
Vivet Therapeutics latest funding size
Time since last funding
|a year ago|
Vivet Therapeutics investors
|Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital|
Vivet Therapeutics has 83 Twitter Followers. The number of followers has increased 9.5% month over month and increased 28.5% quarter over quarter